Prokineticin‐2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients

Background Elevated levels of prokineticin‐2 (PK2), regarded as a protein involved in modulating immune/inflammatory responses, have been detected in the substantia nigra, serum, and olfactory neurons of Parkinson's disease (PD) patients. Of note, emerging evidence suggests that gut alterations...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 39; no. 11; pp. 2091 - 2097
Main Authors Bellini, Gabriele, Rettura, Francesco, Palermo, Giovanni, Ippolito, Chiara, Segnani, Cristina, Pierucci, Clarissa, Fontanelli, Lorenzo, Frosini, Daniela, Nardini, Vincenzo, Lambiase, Christian, Bernardini, Nunzia, Pellegrini, Carolina, Ceravolo, Roberto
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.11.2024
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Elevated levels of prokineticin‐2 (PK2), regarded as a protein involved in modulating immune/inflammatory responses, have been detected in the substantia nigra, serum, and olfactory neurons of Parkinson's disease (PD) patients. Of note, emerging evidence suggests that gut alterations, including dysbiosis and enteric inflammation, play a role in PD via the gut‐brain axis. Objectives Our goal was to investigate the expression of PK2 in colonic biopsies of PD patients. Methods Mucosal biopsies from the descending colon were obtained in 11 PD patients and five asymptomatic subjects. Biopsy samples were processed for PK2 immunofluorescence and western blot. Results We revealed an increased PK2 expression in colonic mucosa from PD patients in the early stages compared to controls. In addition, we found that PK2 was expressed by activated enteric glial cells and macrophages. Conclusions PK2 is highly expressed within neurogenic/inflammatory cells of colonic mucosa from early PD patients, suggesting a potential role of PK2 in gut inflammation, especially in the early stages of PD. © 2024 International Parkinson and Movement Disorder Society.
Bibliography:The authors report no competing interests. No financial disclosures to declare. This research received no specific grant from any funding agency in the public, commercial, or not‐for‐profit sectors.
Relevant conflicts of interest/financial disclosures
Gabriele Bellini and Francesco Rettura equally contributed to this work and should be considered co‐first authors.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0885-3185
1531-8257
1531-8257
DOI:10.1002/mds.29937